Products
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 2017878 | Elenbecestat ( E2609 ) | 1388651-30-6 | ≧98.0% | _1388651-30-6.png) |
| Elenbecestat (E2609) is a potent, orally bioavailable and CNS-penetrant BACE-1 inhibi | ||||
| 2017889 | Roluperidone ( CYR-101 ) | 359625-79-9 | 98.0% | _359625-79-9.png) |
| Roluperidone, also known as MIN-101, CYR-101, and MT-210, is a 5-HT2A and sigma 2 rec | ||||
| 90734 | RSM932A | 850807-63-5 | ≧98.0% | .png) |
| Choline kinase α (CHKA; here designated as ChoKα) is the first enzyme in the CDP-ch | ||||
| 121805 | L-778123 hydrochloride | 253863-00-2 | 98% |  |
| L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and | ||||
| 90102 | Fevipiprant ( NVP-QAW039 ) | 872365-14-5 | ≧98.0% | _872365-14-5.png) |
| Fevipiprant (QAW039; NVP-QAW039) is a selective, potent, reversible competitive CRTh2 | ||||
| 2073106 | Lerociclib HCl (G1T38 HCl) | 2097938-59-3 | ≧98.0% |  |
| Lerociclib HCl (G1T38)is a novel, selective,differentiated oral CDK4/6 inhibitor with | ||||
| S510902 | Cenicriviroc ( TAK-652 ) | 497223-25-3 | 98% Min. |  |
| Cenicriviroc ( TAK-652, TBR-652) is an experimental drug candidate for the treatment | ||||
| 1711222 | Asciminib ( ABL001 ) | 1492952-76-7 | 99.35% |  |
| Asciminib, Bulk in stock, contact us by email for the quotation. Kg scale intermediat | ||||
| 181121 | AZD-5904 | 618913-30-7 | >98% |  |
| AZD5904 is a potent orally bioavailable MPO inhibitor. In preclinical studies, AZD590 | ||||
| 18381 | JPH203 HCl ( Nanvuranlat ) | 1597402-27-1 | ≧95.0% | _1597402-27-1.png) |
| JPH203, also known as KYT-0353, is a potent and selective LAT1 selective ( L-type ami | ||||
| 18382 | eCF506 ( NXP 900 ) | 1914078-41-3 | ≧98.0% |  |
| eCF506 targets a molecule called Src tyrosine kinase that is required for breast canc | ||||
| 184321 | Ensartinib ( X396 ) | 1370651-20-9 | >98% | _1370651-20-9.png) |
| Ensartinib is an orally available small molecule inhibitor of the receptor tyrosine k | ||||